Three Years, 7 Acquisitions Later, Cardinal Health Has More Plans In China
This article was originally published in PharmAsia News
U.S. distributor Cardinal Health goes full speed ahead in China. It has bought local players to tap into the regional market, doubled direct-to-patient pharmacies, and provided pharmacy management services to large hospitals among endeavors in the past three and a half years with more to come.
You may also be interested in...
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
A former pharma executive shares views with Scrip about the coronavirus in China, the challenges facing corporations and individuals in a rapidly changing world and coming threats that could potentially cause even more damage than the pandemic.